Treatment-refractory anti-laminin 332 mucous membrane pemphigoid;Therapieresistentes Anti-Laminin-332-Schleimhautpemphigoid

Hautarzt

Volumn 62, Issue 11, 2011, Pages 852-858

  Recke, A ^a   Shimanovich, I ^a   Steven, P ^a   Westermann, L ^a   Zillikens, D ^a   Schmidt, E ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Autoantibody; Immunoblotting; Immunosuppression; Paraneoplastic syndromes; Pemphigoid

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; KALININ; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN ANTIBODY; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONJUNCTIVA; DRUG EFFECT; DRUG EFFICACY; EROSION; HUMAN; IMMUNOADSORPTION; MALE; MUCOUS MEMBRANE PEMPHIGOID; REMISSION; SYMPTOM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; REMISSION INDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 82955163163     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-011-2189-7     Document Type: Article

References (22)

1. Chan LS, Ahmed AR, Anhalt GJ, et al. (2002) The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 138:370-379 (Pubitemid 34226335)
2. Egan CA, Reddy D, Nie Z, et al. (2001) IgG anti-LABD97 antibodies in bullous pemphigoid patients sera react with the mid-portion of the BPAg2 ectodomain. J Invest Dermatol 116:348-350 (Pubitemid 32173742)
3. Hertl M, Zillikens D, Borradori L, et al. (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6:366-373
4. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. (2011) Rituximab for treatmentrefractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol [Epub ahead of print]
5. Kirtschig G, Marinkovich MP, Burgeson RE, et al. (1995) Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 105:543-548
6. Kirtschig G, Murrell D, Wojnarowska F, et al. (2002) Interventions for mucous membrane pemphigoid/ cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 138:380-384 (Pubitemid 34226336)
7. Lazarova Z, Yee C, Darling T, et al. (1996) Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98:1509-1518 (Pubitemid 26327858)
8. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. (2011) Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol [Epub ahead of print]
9. Leverkus M, Schmidt E, Lazarova Z, et al. (1999) Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring auto immune subepidermal bullous diseases? Arch Dermatol 135:1091-1098 (Pubitemid 29430500)
10. Lourari S, Herve C, Doffoel-Hantz V, et al. (2010) Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol [Epub ahead of print]
11. Luftl M, Stauber A, Mainka A, et al. (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598-605 (Pubitemid 37281594)
12. Meyer-Ter-Vehn T, Schmidt E, Zillikens D, et al. (2008) Mucous membrane pemphigoid with ocular involvement. Part II: therapy. Ophthalmologe 105:405-419
13. Pfutze M, Eming R, Kneisel A, et al. (2009) Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218:237-245
14. Saw VP, Dart JK, Rauz S, et al. (2008) Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 115:253-261
15. Schmidt E, Goebeler M (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 3:259-278
16. Schmidt E, Klinker E, Opitz A, et al. (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222-1229 (Pubitemid 36819223)
17. Schmidt E, Meyer-Ter-Vehn T, Zillikens D, et al. (2008) Mucous membrane pemphigoid with ocular involvement. Part I: clinical manifestations, pathogenesis and diagnosis. Ophthalmologe 105:285-297, quiz 298
18. Schmidt E, Skrobek C, Kromminga A, et al. (2001) Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra-and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 145:778-783 (Pubitemid 33078348)
19. Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241-253
20. Schmidt E, Zillikens D (2009) Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 7:296-300
21. Shimanovich I, Nitschke M, Rose C, et al. (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382-328
22. Zillikens D, Derfler K, Eming R, et al. (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881-887